TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24950218

Group type: EXPERIMENTAL
Intervention: Activity monitor displaying feedback about steps and energy consumed
Number of subjects: 104

Group type: COMPARATOR
Intervention: Blinded monitor (control)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Team competition (Phase 2)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Team competition (Control)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: All participants (Phase 2)
Number of subjects: 104
Study: 20685168

Group type: EXPERIMENTAL
Intervention: Patient focused music (audio pillow)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Loudspeaker music
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (usual sound environment)
Number of subjects: 98
Study: 19589164

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment for malaria (IPTp) using sulfadoxine-pyrimethamine (SP)
Number of subjects: 209
Study: 17224353

Group type: EXPERIMENTAL
Intervention: Traditional bone setting
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 61
Study: 15310785

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11173314

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 317
Study: 9576446

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg b.i.d.
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 7932892

Group type: EXPERIMENTAL
Intervention: Immune-enhancing diet (n = 51)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard stress enteral formula (n = 47)
Number of subjects: 98
Study: 3652696

Group type: EXPERIMENTAL
Intervention: Food additives (preservatives and food colorings)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 30632425

Group type: EXPERIMENTAL
Intervention: 1,3-Butanediol (BD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 28356091

Group type: EXPERIMENTAL
Intervention: Kundalini yoga
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 159

Group type: COMPARATOR
Intervention: Evidence-based advice
Number of subjects: 159
Study: 26474679

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol 500/20 μg b.i.d.
Number of subjects: 309

Group type: COMPARATOR
Intervention: Fluticasone propionate/formoterol 100/10 μg b.i.d.
Number of subjects: 309
Study: 23361929

Group type: EXPERIMENTAL
Intervention: Limited medial parapatellar (MPP) approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mini-midvastus (MV) approach
Number of subjects: 60
Study: 21310551

Group type: EXPERIMENTAL
Intervention: Dronabinol 20mg twice a day
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 18493699

Group type: EXPERIMENTAL
Intervention: Shared Medical Appointment (SMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Process redesign intervention (proactive contact)
Number of subjects: 0
Study: 17581796

Group type: EXPERIMENTAL
Intervention: Informed consent process quality
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Participants' self-perception of knowledge
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Overall trial satisfaction
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Correlation between knowledge and satisfaction
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Age association with knowledge level
Number of subjects: 114
Study: 12755528

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol 50 microg every 4 h
Number of subjects: 106

Group type: COMPARATOR
Intervention: Oral misoprostol 50 microg every 4 h
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 10868559

Group type: EXPERIMENTAL
Intervention: E2 1 mg/NGM 90 microg
Number of subjects: 221

Group type: COMPARATOR
Intervention: E2/NETA 1 mg
Number of subjects: 221
Study: 9188961

Group type: EXPERIMENTAL
Intervention: Ceramaflex brackets (TP Orthodontics Inc, LaPorte, Ind)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transcend 6000 brackets (Unitek Corp, Monrovia, Calif)
Number of subjects: 40
Study: 1300519

Group type: EXPERIMENTAL
Intervention: Advent (fluoropolymer) lens
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Soft lens (Bausch & Lomb U4)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Polymethyl methacrylate (PMMA), silicone acrylate, and fluorosilicone acrylate lenses
Number of subjects: 6

Group type: COMPARATOR
Intervention: Rigid lenses
Number of subjects: 6

Group type: COMPARATOR
Intervention: Rigid lenses (excluding Advent)
Number of subjects: 6
Study: 3745524

Group type: EXPERIMENTAL
Intervention: 0.3% anthralin with 2% salicylic acid in petrolatum
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increasing concentrations of anthralin (0.3%, 1%, 3%) with 2% salicylic acid in petrolatum
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increasing concentrations of anthralin (0.3%, 1%, 3%) for patients who failed to respond to UVB therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: 2% salicylic acid in petrolatum alone
Number of subjects: 15
Study: 31696762

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents (BP-SES)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents (DP-EES)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Both BP-SES and DP-EES
Number of subjects: 486
Study: 30400117

Group type: EXPERIMENTAL
Intervention: VR training for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home-based traditional balance exercises
Number of subjects: 40
Study: 26954876

Group type: EXPERIMENTAL
Intervention: Oral dyclonine hydrochloride mucilage (ODHM)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Tetracaine spray (TS)
Number of subjects: 932
Study: 25019119

Group type: EXPERIMENTAL
Intervention: Conservative treatment with occlusal splint and analgesic and muscle relaxant medication (Group A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Invasive prosthodontic procedures (Group B)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (Group C) - patients who refused treatment
Number of subjects: 70
Study: 22238631

Group type: EXPERIMENTAL
Intervention: Dense cranial electroacupuncture stimulation (DCEAS)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Noninvasive electroacupuncture (n‐EA)
Number of subjects: 73
Study: 20714820

Group type: EXPERIMENTAL
Intervention: Minimal contact Internet-based diabetes self-management program
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Moderate contact Internet-based diabetes self-management program
Number of subjects: 463

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 463
Study: 18508951

Group type: EXPERIMENTAL
Intervention: Midostaurin 25 mg bid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Midostaurin 50 mg bid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Midostaurin 75 mg bid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Midostaurin 75 mg tid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Single oral 100 mg dose
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Midostaurin with high-fat meal
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Midostaurin 50 to 225 mg/day
Number of subjects: 13
Study: 15910012

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg before MDMA 100 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo before MDMA 100 mg
Number of subjects: 7
Study: 12870566

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg b.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10887306

Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microgram, 2 puffs 4 times daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8656680

Group type: EXPERIMENTAL
Intervention: Prednimustine/mitoxantrone (PmM)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine, prednisone (COP)
Number of subjects: 246
Study: 14621753

Group type: EXPERIMENTAL
Intervention: Sequential course of 14 days conventional immunosuppression (ALG, azathioprine, steroids) followed by cyclosporine and steroids
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional immunosuppression for 2 days followed by cyclosporine and steroids
Number of subjects: 114
Study: 4081351

Group type: EXPERIMENTAL
Intervention: Puncture of thoracic pain points (n = 8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Puncture in extrathoracic zones (lower limbs) (n = 9)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both techniques (thoracic and extrathoracic puncture)
Number of subjects: 17
Study: 29308844

Group type: EXPERIMENTAL
Intervention: Complex Contrast Training (CCT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional Strength Training (TST)
Number of subjects: 22
Study: 28952459

Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 72
Study: 27036555

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) lansoprazole
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study: 25291127

Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius LS01 with S. thermophilus ST10 and tara gum (probiotic group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 25
Study: 22604276

Group type: EXPERIMENTAL
Intervention: Home-based telemonitored cardiac rehabilitation (HTCR)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tele-event-Halter ECG facility
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Automatic ECG recordings
Number of subjects: 75
Study: 19910293

Group type: EXPERIMENTAL
Intervention: Intracoronary BMC
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 18056516

Group type: EXPERIMENTAL
Intervention: Computer navigation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Knowledge of results
Number of subjects: 45
Study: 16082736

Group type: EXPERIMENTAL
Intervention: Individualized treatment (peginterferon monotherapy for 48 weeks or shorter combination therapy for 24 weeks for RVR; triple therapy with histamine for 48 weeks or prolonged combination therapy for 72 weeks for SPR; triple therapy for FPR; high-dose peginterferon (360 microg/week) plus ribavirin for NUR)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard treatment (peginterferon alfa-2a 180 microg/week and ribavirin 1000-1200 mg/day)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Histamine (1 mg/day) in addition to peginterferon and ribavirin
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: High-dose peginterferon (360 microg/week) plus ribavirin
Number of subjects: 270
Study: 11374121

Group type: EXPERIMENTAL
Intervention: Active Recovery (AR) for 15 min at 50% of VO2max after 60 min of uphill running at 83% of VO2max
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Complete Rest (RR)
Number of subjects: 13
Study: 9042563

Group type: EXPERIMENTAL
Intervention: Upright posture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 0
Study: 7952988

Group type: EXPERIMENTAL
Intervention: Combined chlorpromazine (600 mg daily) and electroconvulsive therapy (ECT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 15
Study: 3555510

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), 10 mg/week, orally
Number of subjects: 42

Group type: COMPARATOR
Intervention: Azathioprine (AZA), 100 mg/day, orally
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 42
Study: 2294126

Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH) at a dose of 1 IU/kg.week
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH) at a dose of 1 IU/kg.week + 25 ng/kg.day ethinyl estradiol (E2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (hGH alone)
Number of subjects: 40
Study: 1100683

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine-containing gel used once a day for 4 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo gel used during control period for 4 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Standardized oral hygiene instruction for 12 subjects
Number of subjects: 36
Study: 31940591

Group type: EXPERIMENTAL
Intervention: In vivo Treg depletion (IVTRD) with basiliximab 20 mg IV on day +1 post-ASCT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ex vivo Treg depletion (EVTRD) using anti-CD25 microbeads and CliniMACS device
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no Treg depletion)
Number of subjects: 15
Study: 31446628

Group type: EXPERIMENTAL
Intervention: Brief Illness Perception Questionnaire (Brief‐IPQ)
Number of subjects: 571
Study: 29871195

Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin (ITG), 1 ml of gentamicin sulfate (40 g/L) buffered with 0.5 ml of sodium bicarbonate, administered weekly for 2 times
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intratympanic dexamethasone (ITD), 5 mg for the first two days, then weekly for 4 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin (ITG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intratympanic dexamethasone (ITD)
Number of subjects: 70
Study: 26013113

Group type: EXPERIMENTAL
Intervention: Herbal drug combination (Sinupret® extract Dragees) - daily dosage 3 × 160 mg
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Herbal drug combination (Sinupret® extract Dragees)
Number of subjects: 386
Study: 23812875

Group type: EXPERIMENTAL
Intervention: IDegSimple (once-daily insulin degludec with simple titration algorithm)
Number of subjects: 222

Group type: COMPARATOR
Intervention: IDegStep-wise (once-daily insulin degludec with step-wise titration algorithm)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: IDegSimple
Number of subjects: 222

Group type: COMPARATOR
Intervention: IDegStep-wise
Number of subjects: 222
Study: 22303704

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin calcium (LMWHC) combined with Yinxing Damo Injection (YDI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low molecular weight heparin calcium (LMWHC)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin calcium (LMWHC) combined with YDI
Number of subjects: 62
Study: 19338692

Group type: EXPERIMENTAL
Intervention: Nurse Family Partnership (NFP) home visitation services starting in pregnancy until age 2; n = 93.
Number of subjects: 237

Group type: COMPARATOR
Intervention: Comparison services; n = 144.
Number of subjects: 237
Study: 16767851

Group type: EXPERIMENTAL
Intervention: Screening and brief intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 0
Study: 15065979

Group type: EXPERIMENTAL
Intervention: Postidentification feedback after target-absent lineups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postidentification feedback after target-present lineups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postidentification feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence measure reference point (retrospective vs. current confidence)
Number of subjects: 0
Study: 11134468

Group type: EXPERIMENTAL
Intervention: ABC/3TC/ZDV
Number of subjects: 205

Group type: COMPARATOR
Intervention: 3TC/ZDV
Number of subjects: 205
Study: 9402542

Group type: EXPERIMENTAL
Intervention: Leukoaraiosis in centrum semiovale group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Periventricular leukoaraiosis group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 8481170

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 58
Study: 2963644

Group type: EXPERIMENTAL
Intervention: 0.02 mg (0.04 mg) controlled dosage aerosol
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 0.125 mg ipratropium bromide (ITB)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Intravenous doses between 0.25 mg and 0.5 mg ITB
Number of subjects: 107
Study: 30224391

Group type: EXPERIMENTAL
Intervention: 8-week group-based cognitive remediation therapy (CRT)
Number of subjects: 260

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 260
Study: 26259833

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements
Number of subjects: 358
Study: 24671165

Group type: EXPERIMENTAL
Intervention: A‐CHESS smartphone application (treatment as usual plus A‐CHESS)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 349
Study: 23764181

Group type: COMPARATOR
Intervention: 12 months of trastuzumab (control group)
Number of subjects: 3384

Group type: EXPERIMENTAL
Intervention: 6 months of trastuzumab (experimental group)
Number of subjects: 3384
Study: 19887503

Group type: EXPERIMENTAL
Intervention: Candesartan (4 to 16 mg daily)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 18929814

Group type: EXPERIMENTAL
Intervention: Cyclosporine plus Everolimus (group CE, n = 32)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cyclosporine plus Mycophenolate Mofetil (MMF) (group CM, n = 24)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Tacrolimus plus Mycophenolate Mofetil (MMF) (group TM, n = 25)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cyclosporine plus Everolimus (group CE)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cyclosporine plus Mycophenolate Mofetil (MMF) (group CM)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Tacrolimus plus Mycophenolate Mofetil (MMF) (group TM)
Number of subjects: 108
Study: 17407945

Group type: EXPERIMENTAL
Intervention: Immediate drain release (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed drain release (Group B)
Number of subjects: 100
Study: 12846705

Group type: COMPARATOR
Intervention: Desflurane 0.5 MAC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desflurane 1.0 MAC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desflurane 1.5 MAC
Number of subjects: 20
Study: 11474870

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 80 micrograms
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9519495

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 8214699

Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: thiopental
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: methohexital
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: propofol
Number of subjects: 67
Study: 3117447

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GH releasing factor (GRF)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combined administration of insulin and GRF
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hypoglycaemia
Number of subjects: 6
Study: 31952985

Group type: EXPERIMENTAL
Intervention: Hyponatremia at discharge
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Hyponatremia at discharge among patients who were hyponatremic on admission
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Hyponatremia on admission but normalized serum sodium levels at discharge
Number of subjects: 708
Study: 31420292

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone at home
Number of subjects: 180

Group type: COMPARATOR
Intervention: Intravenous flucloxacillin in hospital
Number of subjects: 180
Study: 29131084

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intensive Relaxation Training (RT)
Number of subjects: 75
Study: 25837194

Group type: EXPERIMENTAL
Intervention: Perineural injection (PN)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Single perivascular infiltration (PV1)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Double perivascular infiltration (PV2)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 78
Study: 24165382

Group type: EXPERIMENTAL
Intervention: LT vaccine
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study: 21574174

Group type: EXPERIMENTAL
Intervention: 45 mg/day vitamin K2
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: 90 mg/day vitamin K2
Number of subjects: 548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study: 19794995

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted autogenic training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Monitoring group
Number of subjects: 53
Study: 16855947

Group type: EXPERIMENTAL
Intervention: Full correction of refractive errors (glasses prescribed for myopia, astigmatism, hyperopia > +0.5 dpt)
Number of subjects: 58
Study: 12973229

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (20 U)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 10703633

Group type: EXPERIMENTAL
Intervention: 20% strontium nitrate in 70% glycolic acid (pH=0.6)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 70% glycolic acid (pH=0.6)
Number of subjects: 8
Study: 8990771

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 500 mg/kg
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 141